Pancreatin
Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines · Published , updated
12236006
Medicine Compliance Aid Stability
Pancrex V tablets · Essential Pharmaceuticals Ltd
Essential Pharmaceuticals Ltd
Pancrex V tablets
Tablets e/c
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Storage temperature must not exceed 15 degrees C
22nd October 2015
Pancrex V capsules · Essential Pharmaceuticals Ltd
Essential Pharmaceuticals Ltd
Pancrex V capsules
Capsules
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Storage temperature must not exceed 15 degrees C.
22nd October 2015
Creon 40,000 · Abbott Healthcare Products Ltd
Abbott Healthcare Products Ltd
Creon 40,000
Capsules e/c granules
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Moisture sensitive product.
22nd October 2015
Nutrizym 22 · Merck Serono
Merck Serono
Nutrizym 22
Capsules e/c mini-tablets
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Needs to be stored in a tightly closed container due to complex administration instructions.
22nd October 2015
Pancrease HL · Janssen-Cilag Ltd
Janssen-Cilag Ltd
Pancrease HL
Capsules e/c mini-tablets
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Store in airtight containers. Has complex administration instructions.
22nd October 2015
Pancrex V tablets Forte · Essential Pharmaceuticals Ltd
Essential Pharmaceuticals Ltd
Pancrex V tablets Forte
Tablets e/c
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Storage temperature must not exceed 15 degrees C
22nd October 2015
Creon 10,000 · Abbott Healthcare Products Ltd
Abbott Healthcare Products Ltd
Creon 10,000
Capsules e/c granules
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Moisture sensitive product.
22nd October 2015
Pancrex V capsules 125 · Essential Pharmaceuticals Ltd
Essential Pharmaceuticals Ltd
Pancrex V capsules 125
Capsules
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Storage temperature must not exceed 15 degrees C.
22nd October 2015
Creon 25,000 · Abbott Healthcare Products Ltd
Abbott Healthcare Products Ltd
Creon 25,000
Capsules (e/c pellets)
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Moisture sensitive product.
22nd October 2015
Lactation Safety Information
-
No published evidence of safety
Not absorbed from the mother’s GI tract
Used in infants >1 month
13th July 2016
New Medicines
Enzepi · Exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer) in infants, children, adolescents and adults
Information
Enzepi
New formulation
Aptalis
Development and Regulatory status
Licence withdrawn
Licence withdrawn
None
Jul 17: The marketing authorisation for Enzepi has been withdrawn at the request of the marketing authorisation holder [4] .
Jul 16: Approved in EU [3].
Apr 16: EU positive opinion for use as a pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer). Enzepi is indicated in infants, children, adolescents and adults [1].
Category
Pancreas powder derived from porcine pancreatic glands containing multiple enzymes, including lipases, amylases, and proteases. Available as gastro-resistant hard capsules (5,000; 10,000; 25,000 and 40,000units).
At least 85% of patients with CF have pancreatic insufficiency so will need to take pancreatic enzymes [2].
Exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer) in infants, children, adolescents and adults
Oral
Trial or other data
01. Apr 16: In issuing its positive opinion, the EU CHMP notes that the benefits with Enzepi are its ability to control consequences of exocrine pancreatic insufficiency such as maldigestion and malabsorption of fats, proteins and carbohydrates, which result in nutritional deficiencies. The most common side effects are gastrointestinal complaints [abdominal pain (16%); flatulence (12%); abdominal distension (7%); diarrhoea and vomiting (6%); constipation (5%); nausea (3%)], and headache occurring in approximately 6% of patients. In clinical trials, most of the side effects were mild to moderate in severity. The most important serious adverse reactions observed with pancreatic enzyme medicinal products are anaphylactic reactions and fibrosing colonopathy [1].